{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:13:21Z","timestamp":1786979601405,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00059-022-05113-x","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T08:02:44Z","timestamp":1650614564000},"page":"220-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["New therapeutic approaches for the treatment of hypertriglyceridemia","Neue Therapieans\u00e4tze f\u00fcr Hypertriglyzerid\u00e4mie"],"prefix":"10.1007","volume":"47","author":[{"given":"Ioanna","family":"Gouni-Berthold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"5113_CR1","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","volume":"77","author":"S Raposeiras-Roubin","year":"2021","unstructured":"Raposeiras-Roubin\u00a0S, Rossell\u00f3\u00a0X, Oliva\u00a0B et al (2021) Triglycerides and residual atherosclerotic risk. J\u00a0Am Coll Cardiol 77:3031\u20133041. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.059","journal-title":"J Am Coll Cardiol"},{"key":"5113_CR2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard\u00a0BG (2016) Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res 118:547\u2013563. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306249","journal-title":"Circ Res"},{"key":"5113_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/HCO.0000000000000839","volume":"36","author":"PK Gill","year":"2021","unstructured":"Gill\u00a0PK, Dron\u00a0JS, Hegele\u00a0RA (2021) Genetics of hypertriglyceridemia and atherosclerosis. Curr Opin Cardiol 36:264\u2013271. https:\/\/doi.org\/10.1097\/HCO.0000000000000839","journal-title":"Curr Opin Cardiol"},{"key":"5113_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs\u00a0U, Parhofer\u00a0KG, Ginsberg\u00a0HN, Hegele\u00a0RA (2020) Clinical review on triglycerides. Eur Heart\u00a0J 41:99\u2013109c. https:\/\/doi.org\/10.1093\/eurheartj\/ehz785","journal-title":"Eur Heart J"},{"key":"5113_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL et\u00a0al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J 41:111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"5113_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/HCO.0000000000000862","volume":"36","author":"O Esan","year":"2021","unstructured":"Esan\u00a0O, Wierzbicki\u00a0AS (2021) Triglycerides and cardiovascular disease. Curr Opin Cardiol 36:469\u2013477. https:\/\/doi.org\/10.1097\/HCO.0000000000000862","journal-title":"Curr Opin Cardiol"},{"key":"5113_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11883-020-00897-x","volume":"23","author":"J-C Fruchart","year":"2021","unstructured":"Fruchart\u00a0J\u2011C, Hermans\u00a0MP, Fruchart-Najib\u00a0J, Kodama\u00a0T (2021) Selective peroxisome proliferator-activated receptor alpha modulators (SPPARM\u03b1) in the metabolic syndrome: is pemafibrate light at the end of the tunnel? Curr Atheroscler Rep 23:3. https:\/\/doi.org\/10.1007\/s11883-020-00897-x","journal-title":"Curr Atheroscler Rep"},{"key":"5113_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5551\/jat.48918","volume":"26","author":"S Yamashita","year":"2019","unstructured":"Yamashita\u00a0S, Masuda\u00a0D, Matsuzawa\u00a0Y (2019) Clinical applications of a\u00a0novel selective PPAR\u03b1 modulator, pemafibrate, in dyslipidemia and metabolic diseases. J\u00a0Atheroscler Thromb 26:389\u2013402. https:\/\/doi.org\/10.5551\/jat.48918","journal-title":"J Atheroscler Thromb"},{"key":"5113_CR9","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.3390\/ijms20225537","volume":"20","author":"S Yamashita","year":"2019","unstructured":"Yamashita\u00a0S, Arai\u00a0H, Yokote\u00a0K et al (2019) Efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1): pooled analysis of phase 2 and 3 studies in dyslipidemic patients with or without statin combination. Int J Mol Sci 20:5537. https:\/\/doi.org\/10.3390\/ijms20225537","journal-title":"Int J Mol Sci"},{"key":"5113_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-021-01291-w","volume":"20","author":"K Yokote","year":"2021","unstructured":"Yokote\u00a0K, Yamashita\u00a0S, Arai\u00a0H et al (2021) Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a\u00a0pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. Cardiovasc Diabetol 20:96. https:\/\/doi.org\/10.1186\/s12933-021-01291-w","journal-title":"Cardiovasc Diabetol"},{"key":"5113_CR11","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1111\/dom.13686","volume":"21","author":"E Araki","year":"2019","unstructured":"Araki\u00a0E, Yamashita\u00a0S, Arai\u00a0H et al (2019) Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study. Diabetes Obes Metab 21:1737\u20131744. https:\/\/doi.org\/10.1111\/dom.13686","journal-title":"Diabetes Obes Metab"},{"key":"5113_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2337\/dc17-1589","volume":"41","author":"E Araki","year":"2018","unstructured":"Araki\u00a0E, Yamashita\u00a0S, Arai\u00a0H et al (2018) Effects of pemafibrate, a\u00a0novel selective PPAR\u03b1 modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 41:538\u2013546. https:\/\/doi.org\/10.2337\/dc17-1589","journal-title":"Diabetes Care"},{"key":"5113_CR13","unstructured":"Clinicaltrials.gov (2017) Pemafibrate to reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabeTes (PROMINENT). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03071692. Accessed 7 Feb 2022"},{"key":"5113_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","volume":"206","author":"AD Pradhan","year":"2018","unstructured":"Pradhan\u00a0AD, Paynter\u00a0NP, Everett\u00a0BM et\u00a0al (2018) Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am Heart\u00a0J 206:80\u201393. https:\/\/doi.org\/10.1016\/j.ahj.2018.09.011","journal-title":"Am Heart J"},{"key":"5113_CR15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/14779072.2021.1955348","volume":"19","author":"J Lazarte","year":"2021","unstructured":"Lazarte\u00a0J, Hegele\u00a0RA (2021) Volanesorsen for treatment of familial chylomicronemia syndrome. Expert Rev Cardiovasc Ther 19:685\u2013693. https:\/\/doi.org\/10.1080\/14779072.2021.1955348","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"5113_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen\u00a0AB, Frikke-Schmidt\u00a0R, Nordestgaard\u00a0BG, Tybj\u00e6rg-Hansen\u00a0A (2014) Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N\u00a0Engl J Med 371:32\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1308027","journal-title":"N Engl J Med"},{"key":"5113_CR17","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1400283","volume":"373","author":"D Gaudet","year":"2015","unstructured":"Gaudet\u00a0D, Alexander\u00a0VJ, Baker\u00a0BF et al (2015) Antisense inhibition of apolipoprotein C\u2011III in patients with hypertriglyceridemia. N\u00a0Engl J Med 373:438\u2013447. https:\/\/doi.org\/10.1056\/NEJMoa1400283","journal-title":"N Engl J Med"},{"key":"5113_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum\u00a0JL, Gaudet\u00a0D, Freedman\u00a0SD et\u00a0al (2019) Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N\u00a0Engl J Med 381:531\u2013542. https:\/\/doi.org\/10.1056\/NEJMoa1715944","journal-title":"N Engl J Med"},{"key":"5113_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11883-021-00914-7","volume":"23","author":"I Akoumianakis","year":"2021","unstructured":"Akoumianakis\u00a0I, Zvintzou\u00a0E, Kypreos\u00a0K, Filippatos\u00a0TD (2021) ANGPTL3 and apolipoprotein C\u2011III as novel lipid-lowering targets. Curr Atheroscler Rep 23:20. https:\/\/doi.org\/10.1007\/s11883-021-00914-7","journal-title":"Curr Atheroscler Rep"},{"key":"5113_CR20","unstructured":"Clinicaltrials.gov (2016) The approach open label study: a study of volanesorsen (formerly IONIS-APOCIIIRx) in participants with familial chylomicronemia syndrome. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02658175. Accessed 7 Feb 2022"},{"key":"5113_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","volume":"9","author":"I Gouni-Berthold","year":"2021","unstructured":"Gouni-Berthold\u00a0I, Alexander\u00a0VJ, Yang\u00a0Q et al (2021) Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a\u00a0multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 9:264\u2013275. https:\/\/doi.org\/10.1016\/S2213-8587(21)00046-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5113_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab820","author":"J-C Tardif","year":"2022","unstructured":"Tardif\u00a0J\u2011C, Karwatowska-Prokopczuk\u00a0E, Amour\u00a0ES et al (2022) Apolipoprotein C\u2011III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehab820","journal-title":"Eur Heart J"},{"key":"5113_CR23","unstructured":"Clinicaltrials.gov (2020) A study of AKCEA-APOCIII-LRx administered to patients with familial chylomicronemia syndrome (FCS) (BALANCE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04568434. Accessed 7 Feb 2022"},{"key":"5113_CR24","unstructured":"Clinicaltrials.gov A study of ISIS 678354 administered to participants with severe hypertriglyceridemia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05079919. Accessed 7 Feb 2022"},{"key":"5113_CR25","unstructured":"Clinicaltrials.gov Study to evaluate ARO-APOC3 in adults with severe hypertriglyceridemia (SHASTA-2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04720534. Accessed 7 Feb 2022"},{"key":"5113_CR26","unstructured":"Clinicaltrials.gov A first in human study of STT-5058, an antibody that binds ApoC3. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04419688. Accessed 7 Feb 2022"},{"key":"5113_CR27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/cells10030597","volume":"10","author":"A Wolska","year":"2021","unstructured":"Wolska\u00a0A, Reimund\u00a0M, Sviridov\u00a0DO et\u00a0al (2021) Apolipoprotein mimetic peptides: potential new therapies for cardiovascular diseases. Cells 10:597. https:\/\/doi.org\/10.3390\/cells10030597","journal-title":"Cells"},{"key":"5113_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw7905","author":"A Wolska","year":"2020","unstructured":"Wolska\u00a0A, Lo\u00a0L, Sviridov\u00a0DO et al (2020) A dual apolipoprotein C\u2011II mimetic-apolipoprotein C\u2011III antagonist peptide lowers plasma triglycerides. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaw7905","journal-title":"Sci Transl Med"},{"key":"5113_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1006\/geno.1999.6041","volume":"62","author":"D Conklin","year":"1999","unstructured":"Conklin\u00a0D, Gilbertson\u00a0D, Taft\u00a0DW et al (1999) Identification of a\u00a0mammalian angiopoietin-related protein expressed specifically in liver. Genomics 62:477\u2013482. https:\/\/doi.org\/10.1006\/geno.1999.6041","journal-title":"Genomics"},{"key":"5113_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/MOL.0000000000000755","volume":"32","author":"F Mohamed","year":"2021","unstructured":"Mohamed\u00a0F, Botha\u00a0TC, Raal\u00a0FJ (2021) Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia. Curr Opin Lipidol 32:213\u2013218. https:\/\/doi.org\/10.1097\/MOL.0000000000000755","journal-title":"Curr Opin Lipidol"},{"key":"5113_CR31","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1194\/jlr.M054882","volume":"56","author":"Y Wang","year":"2015","unstructured":"Wang\u00a0Y, Gusarova\u00a0V, Banfi\u00a0S et al (2015) Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J\u00a0Lipid Res 56:1296\u20131307. https:\/\/doi.org\/10.1194\/jlr.M054882","journal-title":"J Lipid Res"},{"key":"5113_CR32","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","volume":"61","author":"RC Adam","year":"2020","unstructured":"Adam\u00a0RC, Mintah\u00a0IJ, Alexa-Braun\u00a0CA et al (2020) Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. J\u00a0Lipid Res 61:1271\u20131286. https:\/\/doi.org\/10.1194\/jlr.RA120000888","journal-title":"J Lipid Res"},{"key":"5113_CR33","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1111\/dom.14450","volume":"23","author":"P Ling","year":"2021","unstructured":"Ling\u00a0P, Zheng\u00a0X, Luo\u00a0S et al (2021) Targeting angiopoietin-like 3 in atherosclerosis: from bench to bedside. Diabetes Obes Metab 23:2020\u20132034. https:\/\/doi.org\/10.1111\/dom.14450","journal-title":"Diabetes Obes Metab"},{"key":"5113_CR34","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","volume":"363","author":"K Musunuru","year":"2010","unstructured":"Musunuru\u00a0K, Pirruccello\u00a0JP, Do\u00a0R et\u00a0al (2010) Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N\u00a0Engl J Med 363:2220\u20132227. https:\/\/doi.org\/10.1056\/NEJMoa1002926","journal-title":"N Engl J Med"},{"key":"5113_CR35","doi-asserted-by":"publisher","first-page":"E1266","DOI":"10.1210\/jc.2012-1298","volume":"97","author":"I Minicocci","year":"2012","unstructured":"Minicocci\u00a0I, Montali\u00a0A, Robciuc\u00a0MR et\u00a0al (2012) Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a\u00a0clinical and biochemical characterization. J\u00a0Clin Endocrinol Metab 97:E1266\u201375. https:\/\/doi.org\/10.1210\/jc.2012-1298","journal-title":"J Clin Endocrinol Metab"},{"key":"5113_CR36","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1177\/2047487319884378","volume":"27","author":"M Ruscica","year":"2020","unstructured":"Ruscica\u00a0M, Macchi\u00a0C, Fogacci\u00a0F et al (2020) Angiopoietin-like 3 and subclinical peripheral arterial disease: evidence from the brisighella heart study. Eur J Prev Cardiol 27:2251\u20132254. https:\/\/doi.org\/10.1177\/2047487319884378","journal-title":"Eur J Prev Cardiol"},{"key":"5113_CR37","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel\u00a0NO, Khera\u00a0AV, Wang\u00a0X et\u00a0al (2017) ANGPTL3 deficiency and protection against coronary artery disease. J\u00a0Am Coll Cardiol 69:2054\u20132063. https:\/\/doi.org\/10.1016\/j.jacc.2017.02.030","journal-title":"J Am Coll Cardiol"},{"key":"5113_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey\u00a0FE, Gusarova\u00a0V, Dunbar\u00a0RL et\u00a0al (2017) Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N\u00a0Engl J Med 377:211\u2013221. https:\/\/doi.org\/10.1056\/NEJMoa1612790","journal-title":"N Engl J Med"},{"key":"5113_CR39","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","volume":"140","author":"Z Ahmad","year":"2019","unstructured":"Ahmad\u00a0Z, Banerjee\u00a0P, Hamon\u00a0S et al (2019) Inhibition of angiopoietin-like protein 3 with a\u00a0monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation 140:470\u2013486. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.039107","journal-title":"Circulation"},{"key":"5113_CR40","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40265-021-01516-y","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham\u00a0A (2021) Evinacumab: first approval. Drugs 81:1101\u20131105. https:\/\/doi.org\/10.1007\/s40265-021-01516-y","journal-title":"Drugs"},{"key":"5113_CR41","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal\u00a0FJ, Rosenson\u00a0RS, Reeskamp\u00a0LF et\u00a0al (2020) Evinacumab for homozygous familial hypercholesterolemia. N\u00a0Engl J Med 383:711\u2013720. https:\/\/doi.org\/10.1056\/NEJMoa2004215","journal-title":"N Engl J Med"},{"key":"5113_CR42","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","volume":"383","author":"RS Rosenson","year":"2020","unstructured":"Rosenson\u00a0RS, Burgess\u00a0LJ, Ebenbichler\u00a0CF et\u00a0al (2020) Evinacumab in patients with refractory hypercholesterolemia. N\u00a0Engl J Med 383:2307\u20132319. https:\/\/doi.org\/10.1056\/NEJMoa2031049","journal-title":"N Engl J Med"},{"key":"5113_CR43","unstructured":"Clinicaltrials.gov Safety and efficacy following repeat-dose of evinacumab (anti-ANGPTL3) in patients with severe hypertriglyceridemia (sHTG) at risk for acute pancreatitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03452228. Accessed 7 Feb 2022"},{"key":"5113_CR44","unstructured":"American College of Cardiology Evinacumab could help some patients with severe hypertriglyceridemia. https:\/\/www.acc.org\/about-acc\/press-releases\/2021\/05\/15\/21\/19\/evinacumab-could-help-some-patients-with-severe-hypertriglyceridemia. Accessed 7 Feb 2022"},{"key":"5113_CR45","unstructured":"Clinicaltrials.gov Efficacy and safety of evinacumab in adult patients with severe hypertriglyceridemia for the prevention of recurrent acute pancreatitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04863014. Accessed 7 Feb 2022"},{"key":"5113_CR46","unstructured":"Clinicaltrials.gov Study of ARO-ANG3 in healthy volunteers and in dyslipidemic patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03747224. Accessed 7 Feb 2022"},{"key":"5113_CR47","unstructured":"Clinicaltrials.gov Study of ARO-ANG3 in adults with mixed dyslipidemia (ARCHES-2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04832971. Accessed 7 Feb 2022"},{"key":"5113_CR48","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","volume":"377","author":"MJ Graham","year":"2017","unstructured":"Graham\u00a0MJ, Lee\u00a0RG, Brandt\u00a0TA et\u00a0al (2017) Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N\u00a0Engl J Med 377:222\u2013232. https:\/\/doi.org\/10.1056\/NEJMoa1701329","journal-title":"N Engl J Med"},{"key":"5113_CR49","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","volume":"41","author":"D Gaudet","year":"2020","unstructured":"Gaudet\u00a0D, Karwatowska-Prokopczuk\u00a0E, Baum\u00a0SJ et al (2020) Vupanorsen, an N\u2011acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart\u00a0J 41:3936\u20133945. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa689","journal-title":"Eur Heart J"},{"key":"5113_CR50","unstructured":"Clinicaltrials.gov A dose-ranging study with vupanorsen (TRANSLATE-TIMI 70). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04516291. Accessed 7 Feb 2022"},{"key":"5113_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt\u00a0DL, Steg\u00a0PG, Miller\u00a0M et\u00a0al (2019) Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia. N\u00a0Engl J Med 380:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792","journal-title":"N Engl J Med"},{"key":"5113_CR52","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.amjmed.2021.03.014","volume":"134","author":"RP Mason","year":"2021","unstructured":"Mason\u00a0RP, Eckel\u00a0RH (2021) Mechanistic insights from REDUCE-IT STRENGThen the case against triglyceride lowering as a\u00a0strategy for cardiovascular disease risk reduction. Am J Med 134:1085\u20131090. https:\/\/doi.org\/10.1016\/j.amjmed.2021.03.014","journal-title":"Am J Med"},{"key":"5113_CR53","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","volume":"73","author":"DL Bhatt","year":"2019","unstructured":"Bhatt\u00a0DL, Steg\u00a0PG, Miller\u00a0M et al (2019) Effects of Icosapent ethyl on total Ischemic events: from REDUCE-IT. J\u00a0Am Coll Cardiol 73:2791\u20132802. https:\/\/doi.org\/10.1016\/j.jacc.2019.02.032","journal-title":"J Am Coll Cardiol"},{"key":"5113_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11883-021-00919-2","volume":"23","author":"F Picard","year":"2021","unstructured":"Picard\u00a0F, Steg\u00a0PG (2021) Cardiovascular disease risk reduction in mild-moderate hypertriglyceridemia: integrating prescription of omega\u20113 with standard treatment. Curr Atheroscler Rep 23:27. https:\/\/doi.org\/10.1007\/s11883-021-00919-2","journal-title":"Curr Atheroscler Rep"},{"key":"5113_CR55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMe1814004","volume":"380","author":"JJP Kastelein","year":"2019","unstructured":"Kastelein\u00a0JJP, Stroes\u00a0ESG (2019) FISHing for the miracle of eicosapentaenoic acid. N\u00a0Engl J Med 380:89\u201390. https:\/\/doi.org\/10.1056\/NEJMe1814004","journal-title":"N Engl J Med"},{"key":"5113_CR56","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","volume":"41","author":"MJ Budoff","year":"2020","unstructured":"Budoff\u00a0MJ, Bhatt\u00a0DL, Kinninger\u00a0A et\u00a0al (2020) Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart\u00a0J 41:3925\u20133932. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa652","journal-title":"Eur Heart J"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05113-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-022-05113-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05113-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T10:09:26Z","timestamp":1655460566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-022-05113-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["5113"],"URL":"https:\/\/doi.org\/10.1007\/s00059-022-05113-x","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"assertion":[{"value":"23 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I.\u00a0Gouni-Berthold has received personal honoraria for consulting from Amgen, Regeneron, Aegereon, Akcea Therapeutics, Daiichi-Sankyo, Novartis, Pfizer, Sanofi and Amarin. J.\u00a0Schwarz declares that he has no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}